Your Directors' have pleasure in presenting the Thirty First (31^st) Annual Report of your Company together with Audited Accounts for the Financial Year ended 31^st March, 2026.

1. FINANCIAL PERFORMANCE

The summarized Audited Financial Results for the year ended 31^st March, 2026 along with comparative figures for the Previous year is as under:

(' in Lakhs)

2. OPERATING RESULTS

Your Company's Total Income during the financial year under review i.e., year 2025-26 is ' 15,537.37 Lakhs as compared to the previous year 2024-25, '14,859.92 Lakhs. Profit before Tax after other comprehensive income for the year 2025-26 is ' 1,121.35 Lakhs as against ' 396.75 Lakhs in the previous year. Profit after Tax for the year 2025-26 stands at ' 1,134.31 Lakhs as against ' 396.75 Lakhs in the previous year.

3. DIVIDEND

The Board has not declared any dividend for the Financial Year 2025-2026.

4. RESERVES

The Company has not transferred any amount to the general reserves during the year under review.

5. CAPITAL STRUCTURE

The Paid-up Equity Share Capital as on March 31, 2026 was ' 2,365.63 Lakhs. During the year under review the Issued, Subscribed and Paid-up capital has remained the same. The Company has not issued any shares with differential voting rights nor granted stock options nor sweat equity.

6. DEPOSITS

The Company has not accepted / invited any deposits from the public in terms of Section 73 of the Companies Act, 2013.

7. CHANGE IN THE NATURE OF BUSINESS

The Company is engaged in the manufacture and export of Pharmaceutical Products. There is no change in the nature of business during the year under review.

8. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY

There have been no material changes and commitments between the end of the financial year 2025-26 and the date of this report, adversely affecting the financial position of the Company.

9. SUBSIDIARIES, ASSOCIATE AND JOINT VENTURE COMPANIES

The Company does not have any subsidiary, associate or joint venture.

10. LOANS, GUARANTEE AND INVESTMENT UNDER SECTION 186 OF COMPANIES ACT, 2013

During the year under review, the Company did not grant any loans, provide any guarantees, make any investments or provide any security under the provisions of Section 186 of the Companies Act, 2013.

11. BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

I. Composition

The composition of the Board of Directors and its Committees, viz., Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee and Corporate Social Responsibility Committee are constituted in accordance with Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR). The details of Composition of the Board, its Committees, meetings and an overview of the role, terms of reference are provided in the Corporate Governance Report annexed to this Report.

The following changes took place in the composition of Board of Directors:

a) Re-Appointment of Directors:

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, at its meeting held on August 12, 2025, and pursuant to the approval of the Members at the Annual General Meeting held on September 19, 2025, re-appointed Mr. Palamadai Krishnan Sundaresan (DIN: 06954189) and Mrs. Ravichandran Chitra (DIN: 07749125) as Non-Executive Independent Directors of the Company for a second term, commencing from September 19, 2025, and November 12, 2025, respectively.

b) Retirement of Directors:

Mr. Navin Kumar (DIN: 08778662), retired as an Independent Director of the Company, upon completion of his first term, with effect from June 22, 2026.

There were no other changes in the composition of the Board of Directors.

II. Retirement by Rotation

Pursuant to the provisions of Section 152 of the Companies Act, 2013 and the Articles of Association of the Company, Mr. Upendar Mekala Reddy (DIN: 08898174), Director retires by rotation at the ensuing 31^st Annual General Meeting (AGM) of the Company and being eligible, offers himself for re-appointment. Your Board recommends his re-appointment as Director of the Company.

The brief resume of the Director seeking re-appointment and other relevant details, as required under the Companies Act, 2013 and SEBI (LODR) Regulations, 2015, are provided in the Notice convening the 31^st AGM.

The Board of Directors is of the opinion that the Director proposed for re-appointment at the ensuing AGM possess integrity, relevant expertise, and the necessary experience for the respective roles. The Corporate Governance Report, annexed to this Report, also contains the requisite disclosures relating to the Directors.

III. Number of Board Meetings:

The Board of Directors met Eight (8) times during the year under review and the gap between 2 meetings did not exceed 120 days. The details of the Board & Committee Meetings and the attendance of the Directors are provided in the Report on Corporate Governance.

IV. Declaration by Independent Directors & Adherence to Company's Code of Conduct:

The Company has received necessary declaration from each independent director under Section 149(7) of the Companies Act, 2013, that he/ she meets the criteria of independence laid down in Section 149(6) of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All Independent Directors have affirmed compliance to the code of conduct for independent directors as prescribed in Schedule IV to the Companies Act, 2013 and the Company's Code of Conduct for Directors and Senior Management Personnel.

In the opinion of the Board, the Independent Directors, fulfill the conditions of independence specified in Section 149(6) of the Act and Regulation 16(1) (b) of the Listing Regulations. The terms and conditions of appointment of Independent Directors have been disclosed in the website of the company at www.bafnapharma.com.

V. Board Evaluation:

The annual evaluation of the performance of the Board, functioning of its committees, and individual Directors was carried out based on the evaluation criteria prescribed by the Nomination and Remuneration Committee and the SEBI (LODR) Regulations, 2015. The performance review of NonIndependent Directors were carried out by the Independent Directors in their separate meeting held during the year.

VI. Committees Of the Board:

The Board has constituted following committees:

i) . Audit Committee;

ii) . Nomination and Remuneration Committee;

iii) . Stakeholders' Relationship Committee;

iv) . Corporate Social Responsibility Committee.

i) . Audit Committee

In terms of Section 177 of the Companies Act, 2013, and other applicable provisions if any, and as per the Regulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has constituted Qualified and Independent Audit Committee. Presently, the Audit Committee comprises of the following Members:

a) Mr. Navin Kumar* - Chairman

b) Mr. P K Sundaresan** - Chairman

c) Mrs. Ravichandran Chitra - Member

d) Mr. Upendar Mekala Reddy - Member

*Ceased w.e.f June 22, 2026

**Appointed w.e.f June 23, 2026

The terms of reference of the Audit Committee includes matters specified in section 177 of the Companies Act 2013, and Regulation 18 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015. All the recommendations made by the Audit Committee during the year were accepted by the Board of Directors of the Company.

The details of the Audit Committee along with its composition, number of meetings, attendance and terms of reference are provided in the Corporate Governance Report, which forms part of this report.

ii) . Nomination & Remuneration Committee

In terms of Section 178 of the Companies Act, 2013 & other applicable provisions, if any, and as per the Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has constituted Nomination & Remuneration Committee. Presently, the Nomination & Remuneration Committee comprises of the following:

a) Mr. Navin Kumar* - Chairman

b) Mr. P K Sundaresan** - Chairman

c) Mrs. Ravichandran Chitra - Member

d) Mrs. Akila C Raju - Member *Ceased w.e.f June 22, 2026 **Appointed w.e.f June 23, 2026

The Committee consists of only Non-Executive Directors as its members. The details of the Nomination & Remuneration Committee along with its composition, number of meetings, attendance and terms of reference are provided in the Corporate Governance Report, which forms part of this report.

iii). Stakeholders Relationship Committee

In terms of Section 178 of the Companies Act, 2013 & other applicable provisions, if any, and as per the Regulation 20 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has constituted Stakeholders Relationship Committee. Presently, the Stakeholders Relationship Committee comprises of the following Members:

a) Mrs. Ravichandran Chitra - Chairperson

b) Ms. S Hemalatha - Member

c) Mrs. Akila C Raju - Member

The details of the Stakeholders Relationship Committee along with its composition, number of meetings, attendance and terms of reference are provided in the Corporate Governance Report, which forms part of this report.

VII. Details of KMP:

The following are the Key Managerial Personnel of the Company in accordance with the provisions of Section 2(51) read with Section 203 of the Act:

a) Mr. Bafna Mahaveer Chand- Chief Executive Officer

b) Dr. Melagiri Sridhar - Chief Financial Officer

c) Mr. A. Mohanachandran - Company Secretary

12. AUDITORS

a) Statutory Auditor

As per the provisions of Section 139 of the Companies Act, 2013, M/s. Brahmayya & Co, Chartered Accountants, Chennai (ICAI FRN:000511S), were appointed as Statutory Auditors of the Company, for a period of five (5) years from the conclusion of the 27^th Annual General Meeting till the conclusion of 32^nd Annual General Meeting of the Company.

Auditors' Report:

The Auditors' Report on the financial statements of the Company for the financial year ended 31 March 2026 is enclosed with the financial statements, which forms part of this Annual Report.

The Board's replies to the observations made by the Statutory Auditors in their report are as follows:

i) The limited audit trail facility currently available in the accounting software needs to be upgraded to meet the applicable requirements. The Company has

initiated the necessary steps to configure/upgrade the accounting software to enable the recording of an audit trail for all relevant transactions.

ii) The related party transaction referred to in clause (xiii) of Annexure - A to the Auditor's Report was undertaken in the ordinary course of business and on an arm's length basis. The delay in obtaining the ratification of the Audit Committee and the Board of Directors was inadvertent in nature. The transaction was subsequently placed before the Audit Committee and the Board of Directors, which, after due consideration, was ratified.

The other observations and remarks made by the Statutory Auditors in their Report and the Notes to the Financial Statements referred to in the Auditors' Report are selfexplanatory and do not call for any further comments.

Further, there were no instances of fraud reported by the Statutory Auditors during the financial year under review.

b) Internal Auditor

Pursuant to the provisions of Section 138 of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014, the Board, on recommendation of the Audit Committee, has appointed M/s. K S Rao & Co, Chartered Accountants (ICAI FRN. 003109S) as internal auditors of the Company for the financial year 2026-2027.

c) Cost Auditor & Maintenance of Cost Records

Pursuant to section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, the Board of Directors, on recommendation of Audit

Committee, appointed M/s. N. Sivashankaran & Co, Cost Accountants (ICMAI Registration No: 100662) as the Cost Auditor of the Company, to conduct audit of cost records maintained by the Company for financial year 2026 - 2027 at a remuneration of ' 75,000/- (Rupees Seventy Five Thousand Only) excluding applicable taxes, reimbursement of out- of-pocket expenses. In terms of Section 148(3) of the Companies Act, 2013 the remuneration payable to the Cost Auditors, as fixed by the Board, is required to be ratified by the members and the resolution for the ratification of Cost Auditors Remuneration is provided under Item No.3 of the Notice convening the 31^st Annual General Meeting.

The Company maintains all such accounts and records as specified by the Central Government under section 148 (1) of the Companies Act, 2013.

i Secretarial Auditor & Secretarial Audit Report

M/s. A.K. Jain & Associates, Company Secretaries in Practice, Chennai, were appointed as the Secretarial Auditors of the Company as per the members approval accorded at the 30^th AGM of the Company for a period of five years from financial year 2025-26 to financial year 2029-30. The Secretarial Audit Report in Form MR-3 is annexed as Annexure-C to this Report.

Reply to the Qualifications made in the Secretarial Audit Report:

The Board's reply for the qualifications, observations made by the Secretarial Auditor in Secretarial Audit Report for F.Y 2025-2026 is provided hereunder:

13. ANNUAL RETURN:

The copy of the Annual Return (Form MGT-7) for F.Y 2025-2026 is made available in the website of the Company at the weblink www.bafnapharma.com

14. RELATED PARTY TRANSACTIONS

All Related Party Transactions that were entered into during the Financial Year under review were on an arm's length basis, and in the ordinary course of business and were in accordance with the Company's Policy on RPT. There are no materially significant related party transactions made by the Company with Related parties which requires approval of the shareholders / which may have potential conflict with the interest of the Company at large.

All related party transactions are placed before the Audit Committee as also the Board for approval and ratification, wherever applicable. Prior omnibus approval of the Audit Committee is obtained on a yearly basis for the transactions which are repetitive in nature. A statement giving details of the transactions entered into with the related parties, pursuant to the omnibus approval so granted, is placed before the Audit Committee and the Board of Directors for their approval, ratification on a quarterly basis.

During the year under review, the Company did not enter into any material related party transactions that were not in the ordinary course of business or not on an arm's length basis. Further, there were no materially significant related party transactions having the potential to conflict with the interests of the Company. Accordingly, the disclosure of related party transactions in Form AOC-2, as prescribed under Section 134(3)(h) of the Companies Act, 2013 read with Rule 8(2) of the Companies (Accounts) Rules, 2014, is not provided.

The Company has adopted a Policy for dealing with Related Party Transactions which has been uploaded on the Company's website under the web-link www. bafnapharma.com.

15. ENERGY CONSERVATION, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The Company is conscious of its responsibility to conserve the energy and has taken measures in relation to conservation of energy and technology absorption. The prescribed particulars on conservation of energy, technology absorption and foreign exchange earnings and outgo as required under Section 134(3) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014 are furnished in Annexure-A to this Report.

16. CORPORATE SOCIAL RESPONSIBILITY

The Company satisfies the criteria as prescribed in section 135 of the Companies Act, 2013 for applicability of Corporate Social Responsibility (CSR) provisions. The Company has adopted a Corporate Social Responsibility (CSR) Policy outlining various CSR activities to be undertaken by the Company, in accordance with Schedule VII to the Companies Act, 2013. The said policy is made available on the Company's website at the following link www.bafnapharma.com. The Report on CSR Activities is annexed as Annexure-B to this Report.

17. PARTICULARS OF DIRECTORS, KEY MANAGERIAL PERSONNEL AND EMPLOYEES

The Company is continuously focusing on retaining the appropriate talent and increasingly systematizing the HR processes. We have excellent industrial relations across all facilities including the corporate office and strongly believe that the workers will continue to work towards achieving a profitable and productive Company.

The information as per Section 197 (12) of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is provided in Annexure - D to this Report. Further, the information pertaining to Rule 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, pertaining to the names and other particulars of employees is available for inspection at the Registered office of the Company during business hours and pursuant to provisions of Section 136(1) of the Act, the Report and the accounts are being sent to the members excluding this. Any shareholder interested in obtaining a copy of the same may write to the Company Secretary/ Compliance Officer either at the Registered/Corporate Office address or by email to cs@bafnapharma.com.

18. CORPORATE GOVERNANCE

The detailed report on Corporate Governance and Certificate from a Practicing Company Secretary regarding

compliance with requirements of Corporate Governance are annexed as Annexure-E to this Report.

19. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Pursuant to Regulation 34 read with Schedule V of the SEBI (LODR) Regulations, 2015, a detailed review of the business operations, performance, future outlook, major events occurred during the year as well as state of company's affairs is given in the Management Discussion and Analysis Report, which is annexed as Annexure-F to this Report. Certain Statements in the report may be forward-looking. Many factors may affect the actual results, which could be different from what the Directors envisage in terms of future performance & outlook.

20. RISK MANAGEMENT:

Your Company recognizes that risk is an integral part of business and is committed to managing the risks in a proactive and efficient manner. Your Company periodically assesses risks in the internal and external environment, along with the cost of treating risks and incorporates risk treatment plans in the strategy, business and operational plans.

21. ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS:

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations. The Internal Auditors monitor and evaluate the efficacy and adequacy of internal control system in the Company, its compliance with operating systems, accounting procedures and policies of the Company. The internal audit reports were reviewed periodically by the Audit Committee & the Board. Further, the Board annually reviews the effectiveness of the Company's internal control system.

22. DIRECTORS RESPONSIBILITY STATEMENT

In terms of Section 134(3)(c) read with section 134(5) of the Companies Act, 2013, the Directors, to the best of their knowledge and belief, based on the information and explanations obtained by them, confirm that:

a) In the preparation of the annual accounts, the applicable accounting standards had been followed and there were no material departures;

b) Appropriate accounting policies had been selected and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the Profit of the Company for the year under review;

c) Proper and sufficient care had been taken for the maintenance of adequate accounting records

in accordance with the provisions of the Act for safeguarding the assets of the Company, preventing and detecting fraud and other irregularities;

d) The financial statements for the financial year had been prepared on a 'going concern basis;

e) The internal financial controls had been laid down, to be followed by the Company and such internal financial controls were adequate and were operating effectively; and

f) In order to ensure compliance with the provisions of all applicable laws, proper systems had been devised and that such systems were adequate and operating effectively.

23. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS/ COURTS:

There are no significant and material orders passed by the Regulators / Courts which would impact the going concern status of your Company and its future operations.

24. SECRETARIAL STANDARDS

The Company has complied with the applicable Secretarial Standards issued by Institute of Company Secretaries of India (ICSI) as per section 118(10) of the Companies Act, 2013.

25. INSIDER TRADING REGULATIONS

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the code of conduct for prevention of insider trading and the code for corporate disclosures are in force. The Company has adopted a Code of Conduct for Prevention of Insider Trading with a view to regulate trading in securities by the Directors and designated persons of the Company, as per SEBI (Prohibition of Insider Trading) Regulations, 2015.

26. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT THE WORK PLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has a zero tolerance towards sexual harassment. The Company has adopted a policy on prevention of sexual harassment of women at work place and put in place proper dissemination mechanism across the Company. The Company has conducted awareness programs for its employees under the said Act.

The Company has complied with the provisions relating to the constitution of Internal Complaints Committee (ICC) under The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. During

the financial year 2025-2026, the Company has not received any complaint.

27. COMPLIANCE WITH MATERNITY BENEFIT ACT, 1961

During the year under review, the Company has complied with the applicable provisions relating to the Maternity Benefit Act, 1961.

28. VIGIL MECHANISM / WHISTLE BLOWER POLICY

The Board of Directors adopted the Whistle-Blower Policy in accordance with Section 177(9) of the Act, and Regulation 22 of the SEBI (LODR) Regulations, 2015. The policy provides adequate safeguard against victimization and for direct access to the Chairman of the Audit Committee for the employees and state their complaints / grievances. The Whistle Blower Policy is uploaded on the Company's website www.bafnapharma.com.

29. DISCLOSURE UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:

During the year under review, no application was made or any proceeding is pending under the Insolvency and Bankruptcy Code, 2016.

30. DISCLOSURE REGARDING VALUATION UNDER ONE TIME SETTLEMENT:

Not Applicable.

31. ACKNOWLEDGEMENT AND APPRECIATION

The Board takes this opportunity to thank all shareholders, business partners, financial institutions, banks, distributors, suppliers, customers, government and regulatory authorities, etc., for their co-operation and support extended to the Company. The Directors also wish to express their gratitude to the Shareholders for the confidence and faith that they continued to repose in the Company. The Directors place on record their appreciation of the consistent and dedicated services of the employees at all levels who have immensely contributed to the performance of the Company during the year under review.